Abstract
Ototoxicity and nephrotoxicity are dose-limiting side effects of cisplatin. Megalin, a member of the low-density lipoprotein receptor family, is highly expressed in renal proximal tubular cells and marginal cells of the stria vascularis of the inner ear – tissues, which accumulate high levels of platinum–DNA adducts. On the assumption that the mechanisms of cisplatin-induced nephro- and ototoxicity involve megalin we analyzed the incidence of the non-synonymous single nucleotide polymorphisms (SNP) rs2075252 and rs4668123 in 25 patients who developed a distinct hearing loss during cisplatin therapy and in 25 patients without hearing impairment after cisplatin therapy. We found no association between cisplatin-induced ototoxicity and any allele of rs4668123 but observed a higher frequency of the A-allele of rs2075252 in the group with hearing impairment than in the group with normal hearing after cisplatin therapy (0.32 versus 0.14) (χ2=5.83, P<0.02; odds ratio: 3.45; 95% confidence interval: 1.11–11.2) indicating that SNPs at the megalin gene might impact the individual susceptibility against cisplatin-induced ototoxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J . Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991; 19: 295–300.
Laurell G, Jungnelius U . High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990; 100: 724–734.
Weatherly RA, Owens JJ, Catlin FI, Mahoney DH . cis-platinum ototoxicity in children. Laryngoscope 1991; 101: 917–924.
Blakley BW, Gupta AK, Myers SF, Schwan S . Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120: 541–546.
McHaney VA, Thibadoux G, Hayes FA, Green AA . Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983; 102: 314–317.
Schaefer SD, Post JD, Close LG, Wright CG . Ototoxicity of low- and moderate-dose cisplatin. Cancer 1985; 56: 1934–1939.
Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Wurthwein G et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 2006; 47: 183–193.
Boulikas T, Vougiouka M . Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 2003; 10: 1663–1682.
Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73: 1569–1575.
Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J . High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 2006; Mar: 28.
Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C . Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 1986; 94: 458–470.
Schweitzer VG . Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103: 1–52.
Schmitz C, Hilpert J, Jacobsen C, Boensch C, Christensen EI, Luft FC et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277: 618–622.
Schmidt CM, Bartholomaus E, Deuster D, Heinecke A, Dinnesen AG . The ‘Muenster classification’ of high frequency hearing loss following cisplatin chemotherapy. HNO 2006: 26 (Epub ahead of print).
Mizuta K, Saito A, Watanabe T, Nagura M, Arakawa M, Shimizu F et al. Ultrastructural localization of megalin in the rat cochlear duct. Hear Res 1999; 129: 83–91.
Li Y, Womer RB, Silber JH . Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445–2451.
Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K . Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995; 4: 357–362.
de Kok JB, Wiegerinck ET, Giesendorf BA, Swinkels DW . Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum Mutat 2002; 19: 554–559.
Acknowledgements
The data presented in this article fulfill the requirements for the medical doctoral thesis of LR at the University of Muenster, Germany.
Author information
Authors and Affiliations
Corresponding author
Additional information
Duality of Interest
The authors confirm that there is no duality of interest.
Rights and permissions
About this article
Cite this article
Riedemann, L., Lanvers, C., Deuster, D. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8, 23–28 (2008). https://doi.org/10.1038/sj.tpj.6500455
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500455
Keywords
This article is cited by
-
Ototoxicity in Patients of Advanced Head and Neck Malignancies Receiving Chemoradiation Versus Radiation Alone: Comparative Study
Indian Journal of Otolaryngology and Head & Neck Surgery (2022)
-
Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin
Supportive Care in Cancer (2021)
-
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study
The Pharmacogenomics Journal (2020)
-
The genetic vulnerability to cisplatin ototoxicity: a systematic review
Scientific Reports (2019)
-
Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin
The Pharmacogenomics Journal (2017)